Camrelizumab and famitinib are projected to achieve global annual sales of $463 million and $108 million by 2031.
A closely watched trial in Chinese patients is raising hope that ivonescimab will outperform Keytruda in a large global study ...
"ESMO 2025: Padcev plus Keytruda promising in first-line advanced HNSCC" was originally created and published by Clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback